CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
superDimension™ Navigation System Version 7.2device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03585959
NCT03585959N/ACompleted
CompareCT.gov

A Post-market Feasibility Study Evaluating Location Accuracy Using the superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology in Subjects Undergoing Lung Lesion Biopsy

Medtronic - MITG·interventional·Posted Jul 13, 2018·Updated Apr 29, 2020

In Brief

A clinical study evaluating superDimension™ Navigation System Version 7.2 for Lung Cancer. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 13, 2018
Enrollment StartAug 3, 2018
Primary CompletionFeb 13, 2019
Study CompletionFeb 18, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.0 years ago

Interventions

superDimension™ Navigation System Version 7.2device

superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy